20th Feb 2020 14:00
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms E Walmsley | |||
b) | Position/status | Chief Executive Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £0.00 | 37,221 (Deferred) |
| ||
| £0.00 | 24,815 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
62,036 £0.00 | ||||
e) | Date of the transaction | 2020-02-17 | |||
f) | Place of the transaction
| N/A |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms E Walmsley | |||
b) | Position/status | Chief Executive Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £16.614 | 17,523 (Deferred) |
| ||
| £16.614 | 11,680 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
29,203 £16.614 | ||||
e) | Date of the transaction | 2020-02-17 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr R Connor | |||
b) | Position/status | President, Global Vaccines | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £0.00 | 19,375 (Deferred) |
| ||
| £0.00 | 12,917 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
32,292 £0.00 | ||||
e) | Date of the transaction | 2020-02-17 | |||
f) | Place of the transaction
| N/A |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr R Connor | |||
b) | Position/status | President, Global Vaccines | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £16.714 | 9,120 (Deferred) |
| ||
| £16.714 | 6,081 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information
|
| |||
Aggregated volume Price |
15,201 £16.714 | ||||
e) | Date of the transaction | 2020-02-17 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr N Hirons | |||
b) | Position/status | SVP, Global Ethics and Compliance | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £0.00 | 12,243 (Deferred) |
| ||
| £0.00 | 8,163 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
20,406 £0.00 | ||||
e) | Date of the transaction | 2020-02-17 | |||
f) | Place of the transaction
| N/A |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr N Hirons | |||
b) | Position/status | SVP, Global Ethics and Compliance | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £16.678 | 5,770 (Deferred) |
| ||
| £16.678 | 3,846 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information
|
| |||
Aggregated volume Price |
9,616 £16.678 | ||||
e) | Date of the transaction | 2020-02-17 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr B McNamara | |||
b) | Position/status | CEO, GSK Consumer Healthcare | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053 | |||
b) | Nature of the transaction | The sale of ADSs to meet tax liabilities on the vesting of awards under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| $43.544 | 3,467 (Deferred) |
| ||
| $43.544 | 2,423 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
5,890 $43.544 | ||||
e) | Date of the transaction | 2020-02-18 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS)
|
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr D Redfern | |||
b) | Position/status | Chief Strategy Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £0.00 | 15,407 (Deferred) |
| ||
| £0.00 | 10,273 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information
|
| |||
Aggregated volume Price |
25,680 £0.00 | ||||
e) | Date of the transaction | 2020-02-17 | |||
f) | Place of the transaction
| N/A |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr D Redfern | |||
b) | Position/status | Chief Strategy Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £16.629 | 7,261 (Deferred) |
| ||
| £16.629 | 4,840 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
12,101 £16.629 | ||||
e) | Date of the transaction | 2020-02-17 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr P Thomson | |||
b) | Position/status | President, Global Affairs | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £0.00 | 7,302 (Deferred) |
| ||
| £0.00 | 4,869 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information
|
| |||
Aggregated volume Price |
12,171 £0.00 | ||||
e) | Date of the transaction | 2020-02-17 | |||
f) | Place of the transaction
| N/A |
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr P Thomson | |||
b) | Position/status | President, Global Affairs | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £16.623 | 3,442 (Deferred) |
| ||
| £16.623 | 2,294 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
5,736 £16.623 | ||||
e) | Date of the transaction | 2020-02-17 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) |
Related Shares:
Glaxosmithkline